Boston Scientific beefs up heart device portfolio with $14.5 billion Penumbra deal
Boston Scientific said on Thursday it will buy medtech firm Penumbra in a deal valued at about $14.5 billion to expand its portfolio of cardiovascular devices.
Neutral
0.0